deucravacitinib lupus
Selected indexed studies
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. (Arthritis Rheumatol, 2023) [PMID:36369798]
- Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis. (Autoimmun Rev, 2025) [PMID:39694128]
- Oral Deucravacitinib for Treatment-Refractory Cutaneous Lupus Erythematosus. (Cureus, 2025) [PMID:40314052]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. (2023) pubmed
- Deucravacitinib: First Approval. (2022) pubmed
- Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis. (2025) pubmed
- Oral Deucravacitinib for Treatment-Refractory Cutaneous Lupus Erythematosus. (2025) pubmed
- Emerging biologic therapies for systemic lupus erythematosus. (2024) pubmed
- An update on clinical trials for cutaneous lupus erythematosus. (2024) pubmed
- Systemic lupus erythematosus. (2022) pubmed
- Use of Deucravacitinib in Cutaneous Lupus Erythematosus: Two Patient Experiences at a Combined Rheumatology-Dermatology Clinic. (2025) pubmed
- Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management. (2026) pubmed
- Discoid lupus erythematosus successfully treated with deucravacitinib. (2024) pubmed